Cognitive impairment in men with testicular cancer prior to adjuvant therapy
β Scribed by Jeffrey S. Wefel; Damon J. Vidrine; Tracy L. Veramonti; Christina A. Meyers; Salma K. Marani; Harald J. Hoekstra; Josette E. H. M. Hoekstra-Weebers; Lokesh Shahani; Ellen R. Gritz
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 132 KB
- Volume
- 117
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. The presence of multiple determinants of aggressive cancer biology may impact prostate cancerβspecific mortality (PCSM) rates compared with fewer factors. The authors estimated PCSM after radiation therapy with shortβcourse androgen suppression therapy (RT+AST) or radica
T he recent article by Varlotto et al 1 raises issues that are prob- lematic in the recent and current bronchioloalveolar (BAC) literature. The third edition of the 1999 World Health Organization (WHO) consensus classification redefined BAC as an in situ tumor with a pure BAC growth pattern and with
Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a b